logo
‘Ice Cubes in a Volcano': Scientists Baffled by Mysterious Clouds in Center of the Milky Way

‘Ice Cubes in a Volcano': Scientists Baffled by Mysterious Clouds in Center of the Milky Way

Gizmodo4 days ago
In the center of our galaxy, gigantic, balloon-like structures of high-energy radiation extend thousands of light-years above and below the Milky Way's plane. Known as the Fermi bubbles, the massive lobes may have been the result of a violent outburst in our galaxy's recent past. A new discovery of cold hydrogen clouds embedded inside the bubbles adds another level of mystery to the objects, suggesting they're only a few million years old—practically brand-new, by cosmic standards.
Using the National Science Foundation's Green Bank Telescope in West Virginia, a team of scientists discovered something extremely odd. Lurking inside the hot Fermi bubbles are clouds of cold gas that shouldn't be there, forcing scientists to wonder how the cooler gas manages to survive in the superheated, extreme environment. The new findings, published in The Astrophysical Journal Letters, shed light on how galaxies evolve over time.
The Fermi bubbles were discovered in 2010 by NASA's Fermi Gamma-ray Space Telescope. The two orbs form an hourglass structure, one stretching above and another below the center of the Milky Way. Each lobe is around 25,000 light-years tall, made up of gamma rays and high-energy cosmic rays.
'Fermi bubbles are a relatively recent discovery – they were first identified by telescopes that 'see' gamma rays in 2010 – there are different theories about how it happened, but we do know that it was an extremely sudden and violent event, like a volcanic eruption but on a massive scale,' Rongmon Bordoloi, associate professor of physics at North Carolina State University and co-author of the research, said in a statement.
The team behind the study was observing the Fermi bubbles to gather high-resolution data about the composition of the hot gas within the structure. The majority of gas inside the Fermi bubbles is super-hot, measuring at around 1 million degrees Kelvin. Surprisingly, the team also found clouds of neutral hydrogen gas dotted within the bubbles around 12,000 light-years above the center of the galaxy and as massive as several thousand Suns.
The gas in the clouds, however, is relatively cold compared to the rest of the gas in the bubbles. 'They're around 10,000 degrees Kelvin, so cooler than their surroundings by at least a factor of 100,' Andrew Fox, astronomer at the Space Telescope Science Institute and coauthor of the paper, said in a statement. 'Finding those clouds within the Fermi bubble is like finding ice cubes in a volcano.'
Considering their extreme environment, the clouds of hydrogen should have been destroyed, a process that would take over a few million years. This means that the Fermi bubbles are much younger than expected. 'It wouldn't be possible for the clouds to be present at all if the Fermi bubbles were 10 million years old or older,' Bordoloi said.
The scientists behind the study believe that the clouds were swept up from the center of the Milky Way and carried by the hot wind that formed the Fermi bubbles. Jay Lockman, an astronomer at the Green Bank Observatory and coauthor of the paper, compared the system to a more familiar phenomenon: 'Just as you can't see the motion of the wind on Earth unless there are clouds to track it, we can't see the hot wind from the Milky Way but can detect radio emission from the cold clouds it carries along.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Yahoo

time21 minutes ago

  • Yahoo

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Patent-protected methylone-inspired analogs support pipeline expansion into PTSD CAMBRIDGE, Mass., July 23, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. The allowed patent application, titled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," covers a unique series of methylone-inspired compounds, which are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders. "With this second patent allowance for the EVM401 Series, Enveric continues to strengthen its position as a first-in-class developer of neuroplastogenic small-molecule therapeutics," said Joseph Tucker, Ph.D., Director and CEO of Enveric. "These patent-protected molecules are designed to capture the desirable neuroplasticity-promoting effects of methylone, while offering novel chemical structures that enable both strong IP protection and a potential path to repeat-dose outpatient care." Enveric's molecules share pharmacophoric elements with methylone, an MDMA analog recently associated with positive Phase 2 results for post-traumatic stress disorder (PTSD), but differ structurally in ways that render them patentable and proprietary. In contrast, methylone, a synthetic cathinone with structural limitations, has no available composition of matter patent exclusivity because its structure is in the public domain. Enveric's differentiated benzodioxole analogs may offer similar therapeutic promise while potentially enabling a clearer regulatory and commercial path. The Company expects further preclinical testing will be required to evaluate safety, pharmacokinetics, and functional activity against PTSD and other psychiatric endpoints. "The expansion of the EVM401 Series reflects Enveric's commitment to developing a deep pipeline of next-generation, non-hallucinogenic neuroplastogens that align with the scalability and safety needs of modern mental health treatment," added Dr. Tucker. "We believe this patent further positions Enveric at the forefront of the development of a new wave of targeted, accessible neuroplastogenic small-molecule drugs" About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. View source version on Contacts Investor RelationsTiberend Strategic Advisors, Inc. David Irish(231) 632-0002dirish@ Media RelationsTiberend Strategic Advisors, Inc. Casey McDonald(646) 577-8520cmcdonald@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models
Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models

Associated Press

timean hour ago

  • Associated Press

Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models

SAN DIEGO--(BUSINESS WIRE)--Jul 23, 2025-- the leading R&D procurement orchestration platform for the life sciences, today announced a major expansion of its Tumor Model Finder (TMF) following a strategic partnership with XenoSTART, a global leader in patient-derived xenograft (PDX) model development and testing. The addition of hundreds of unique and high-demand XenoSTART models pushes the TMF past a milestone of 10,000 searchable oncology models, giving cancer researchers unprecedented access to diverse and clinically relevant tools. 'Pharma discovery teams often face critical delays accessing translational research partners with deeply characterized PDX models that accurately reflect real-world patient disease complexity,' said Michael J. Wick, PhD, Chief Scientific Officer at XenoSTART. 'By joining the marketplace, XenoSTART eliminates this significant barrier, providing immediate access to our highly relevant, patient-derived tumor models that are directly linked to our global clinical network. This integration empowers drug developers to confidently accelerate therapeutic decision-making and precisely guide their translational strategies—ultimately speeding effective cancer treatments to patients.' Tumor Model Finder is a centralized, AI-powered platform that aggregates and standardizes tumor model data from 20+ leading CROs. It allows researchers to search, compare, and source PDX, CDX, organoid, and cell line models—spanning 17 cancer types—through a single workflow. The platform also includes drug response profiles, genomic alterations (e.g., KRAS, BRAF mutations), and RNA seq-based gene expression data to support informed model selection and study design. 'XenoSTART's contribution significantly boosts the depth and quality of our TMF offerings,' said Javier Pineda, PhD, Director of Preclinical AI at 'Researchers can now find models with richer data and greater relevance to their specific cancer studies.' This collaboration also highlights the translational impact of START's global research ecosystem. With patient-derived tissue samples sourced from START's expansive oncology trial network, XenoSTART's models provide critical continuity between preclinical evaluation and clinical trial execution—helping pharmaceutical companies make faster, more confident decisions in oncology drug development. To learn more or schedule a demo of the Tumor Model Finder, email [email protected]. About is the life-science industry's premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world's top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Visit to discover how we accelerate science. About XenoSTART Founded in 2007, XenoSTART is a translational research organization dedicated to advancing oncology drug development through clinically relevant preclinical cancer models. The XenoSTART Patient-Derived Xenograft (XPDX) platform features more than 2,800 models across a broad range of tumor types and disease stages sourced from patients treated at START's domestic and international cancer centers. Models are deeply characterized using histologic analysis, DNA/RNA sequencing, and in vivo drug sensitivity testing, and are clinically annotated with the donor patient's treatment history and clinical outcome. By bridging real-world tumor biology with rigorous preclinical science, XenoSTART enables pharmaceutical partners to make smarter, faster decisions from bench to bedside. Learn more about XenoSTART at View source version on CONTACT: Sean Preci +1 877-644-3044 [email protected] XenoSTART Lauren Panco 609-216-4920 KEYWORD: EUROPE UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: OTHER HEALTH RESEARCH PHARMACEUTICAL ONCOLOGY TECHNOLOGY ARTIFICIAL INTELLIGENCE GENETICS HEALTH TECHNOLOGY SCIENCE BIOTECHNOLOGY OTHER SCIENCE HEALTH SOURCE: Copyright Business Wire 2025. PUB: 07/23/2025 07:55 AM/DISC: 07/23/2025 07:55 AM

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Associated Press

timean hour ago

  • Associated Press

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

DALLAS--(BUSINESS WIRE)--Jul 23, 2025-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug discovery paradigms, today announces that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase 1 clinical trial of LP-284. This represents the first complete response observed with LP-284 and displays profound clinical activity in one of the most therapeutically challenging hematologic cancers. The RADR®-driven, AI approach enables Lantern to rapidly determine mechanisms of action of any cancer focused molecule, identify biomarker-driven subpopulations and optimize combination strategies for the clinical setting. The 41-year-old patient had previously failed three aggressive treatment regimens over 18 months over the last 15 months. These included: standard R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy (liso-cel), and CD3xCD20 bispecific antibody therapy (glofitamab). Following enrollment in April 2025, the patient achieved complete metabolic response with non-avid lesions after completing just two 28-day cycles of LP-284 administered on days one, eight, and 15. This remarkable clinical outcome supports LP-284's synthetic lethal mechanism and is an initial step towards a potential new paradigm for treating refractory aggressive lymphomas and B-cell malignancies. Paradigm-Shifting Observation of Complete Response in Therapeutically Exhausted Patient 'This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm,' said Panna Sharma, President and CEO of Lantern Pharma. 'Our RADR® platform's systematic analysis of molecular vulnerabilities enabled us to rapidly advance LP-284 from computational concept to a clinical milestone in a patient in under three years at approximately $3 million — demonstrating how AI-driven precision has the promise to fundamentally reshape pharmaceutical innovation. This complete metabolic response in a patient who had exhausted all conventional therapeutic options strongly supports our strategic thesis that computational approaches can unlock previously inaccessible therapeutic opportunities.' LP-284, a computationally optimized next-generation acylfulvene, was systematically developed with guidance from Lantern's RADR® platform to exploit synthetic lethal interactions in cancer cells harboring specific DNA damage repair deficiencies. The compound represents a fundamentally different therapeutic strategy with the potential to preferentially target malignant cells while preserving healthy tissue function — a precision approach aimed at delivering transformative clinical benefit for patients who have failed multiple prior treatment modalities. Potential to Address a Critical Therapeutic Void in Refractory DLBCL This patient's clinical journey exemplifies the devastating trajectory of aggressive DLBCL in the refractory setting. Despite achieving an initial complete metabolic response with CAR-T therapy (liso-cel) at day 30, the patient experienced disease progression by day 90. Subsequent treatment with the CD3xCD20 bispecific antibody glofitamab resulted in progressive disease with multifocal new lesions. At study entry on the LP-284-Phase 1 trial in April 2025, the patient presented with extensive multifocal bony lesions across thoracic and lumbar spine locations and hips — representing an extremely challenging clinical scenario. The achievement of complete metabolic response with non-avid lesions following just two cycles of LP-284 therapy represents a potential future paradigm-shifting alternative for treating therapeutically exhausted DLBCL patients. This encouraging outcome underscores LP-284's potential to address critical gaps in the therapeutic armamentarium for patients who have failed both conventional and cutting-edge immunotherapeutic approaches. Advancing Strategic Clinical Development and Global Expansion The complete metabolic response achievement positions LP-284 for accelerated development pathways and strengthens Lantern's strategic position in the competitive hematologic oncology landscape. This clinical milestone provides important confirmation of the company's systematic approach to therapeutic development and creates additional opportunities for international partnership expansion and collaborative research initiatives. Lantern's ongoing Phase 1 dose-escalation study (NCT06132503) is designed to evaluate LP-284's safety profile, optimal dosing parameters, and preliminary efficacy signals across multiple aggressive lymphoma subtypes. The trial's systematic design enables precise evaluation of LP-284's therapeutic potential across genetically defined patient populations, with a current focus on aggressive NHL subtypes including mantle cell lymphoma and high-grade B-cell lymphomas. LP-284's multiple FDA Orphan Drug Designations position the compound for potential expedited regulatory pathways and enhanced market exclusivity frameworks. Transforming Global Oncology Through Computational Precision This clinical development provides important confirmation of the transformative potential of Lantern's RADR® platform, which leverages over 200 billion oncology-focused data points and 200+ machine learning algorithms to assist in systematically identifying and optimizing therapeutic opportunities. The platform's computational efficiency enabled Lantern to rapidly advance the LP-284's program into the clinic in under three years at a cost of approximately $3 million — representing striking development efficiency compared to traditional pharmaceutical paradigms. The complete metabolic response achievement positions LP-284 to seek a future role within a global blood cancer market focused on B-cell cancer that is estimated at $4 billion annually, with DLBCL representing the largest aggressive lymphoma subtype affecting approximately 200,000 patients globally each year. The critical unmet need in refractory/relapsed settings represents a substantial commercial opportunity for innovative therapeutic approaches that can deliver meaningful clinical benefit to therapeutically exhausted patient populations. Next Steps and Future Development Lantern plans to continue enrollment in the Phase 1 trial while closely monitoring the responding patient and other potential future patients for durability of response and efficacy signals. The company anticipates providing additional clinical updates as the trial progresses and more patients reach evaluable timepoints. The complete response achievement positions LP-284 for potential accelerated development pathways and creates opportunities for strategic partnerships as Lantern advances its synthetic lethal portfolio toward later-stage clinical trials. About LP-284 LP-284 is an investigational next-generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA damage repair deficiencies. Developed with guidance from Lantern's AI platform RADR®, LP-284 represents a novel therapeutic approach with potential to address critical gaps in the treatment of relapsed or refractory non-Hodgkin's lymphoma and other hematologic malignancies. The compound is currently being evaluated in a Phase 1 clinical trial (NCT06132503) to determine its safety profile, optimal dosing, and potential activity in patients with aggressive NHL subtypes who have failed standard therapies. LP-284 has received multiple Orphan Drug Designations from the U.S. Food and Drug Administration, including designations for mantle cell lymphoma and high-grade B-cell lymphomas, recognizing its potential to address significant unmet medical needs in rare cancer populations. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its proprietary RADR® platform leverages artificial intelligence and machine learning with the aim of uncovering novel therapeutic opportunities, accelerating drug development timelines, and improving patient outcomes. The company's approach combines advanced computational biology with traditional pharmaceutical development to transform how cancer drugs are discovered and developed. For more information, visit: - Website: ( ) - LinkedIn: - X: @lanternpharma ( Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'model,' 'objective,' 'aim,' 'upcoming,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024, under the investor SEC filings tab of our website at ( ) or on the SEC's website at ( ). Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. View source version on CONTACT: Investor Contact Investor Relations [email protected] +1-972-277-1136 KEYWORD: UNITED STATES NORTH AMERICA TEXAS INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: Lantern Pharma Inc. Copyright Business Wire 2025. PUB: 07/23/2025 07:56 AM/DISC: 07/23/2025 07:56 AM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store